![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The aim of the present work is to formulate heparin-modified-polycaprolactone (HEP) core shell nanoparticles (NPs) of 5-fluorouracil (5-FU). These NPs were characterized for various in vitro parameters like particle size, zeta potential, etc. HEP NPs were found to maintain comparatively slower drug release pattern (98.9% in 96 h) than PCL NPs. Cytotoxicity studies demonstrated a massive cytotoxic potential of 5-FU-loaded HEP NPs in A549, MDA-MD-435, and SK-OV-3 cancer cell lines. Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.
Acknowledgements
The author acknowledges SAIF-CDRI (Lucknow, India) for NMR facility and Indian Institute of Technology (Indore, India) for providing AFM facility. The author expresses his sincere thanks to Indian Institute of Technology (Ropar, India) for providing XRD facility. The author also expresses his sincere thanks to SAIF-RGPV (Bhopal, India) for providing particle size and zeta potential facilities, and also expresses his sincere thanks to ACTREC (Mumbai, India) for providing in vitro cytotoxicity assay facility.
Disclosure statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Funding information
The present research work was financially supported by MPCST, Bhopal (MP), India (Grant Number: 1766/CST/R&D/Bio, Proj/2013).